Your browser is no longer supported. Please, upgrade your browser.
Settings
ARWR Arrowhead Pharmaceuticals, Inc. daily Stock Chart
ARWR [NASD]
Arrowhead Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.68 Insider Own2.60% Shs Outstand86.48M Perf Week-4.36%
Market Cap1.14B Forward P/E- EPS next Y-0.51 Insider Trans-10.68% Shs Float80.44M Perf Month-30.46%
Income-54.40M PEG- EPS next Q-0.11 Inst Own61.40% Short Float19.13% Perf Quarter-20.06%
Sales13.60M P/S83.62 EPS this Y65.20% Inst Trans3.67% Short Ratio6.04 Perf Half Y91.97%
Book/sh1.17 P/B11.24 EPS next Y19.00% ROA-50.40% Target Price23.30 Perf Year228.75%
Cash/sh0.70 P/C18.80 EPS next 5Y7.33% ROE-59.00% 52W Range3.01 - 22.39 Perf YTD257.34%
Dividend- P/FCF- EPS past 5Y24.50% ROI-44.10% 52W High-41.27% Beta2.04
Dividend %- Quick Ratio8.70 Sales past 5Y192.40% Gross Margin- 52W Low336.88% ATR1.41
Employees93 Current Ratio8.70 Sales Q/Q-92.50% Oper. Margin- RSI (14)32.42 Volatility8.89% 8.38%
OptionableYes Debt/Eq0.02 EPS Q/Q-141.20% Profit Margin- Rel Volume0.74 Prev Close13.11
ShortableYes LT Debt/Eq0.02 EarningsNov 06 AMC Payout- Avg Volume2.55M Price13.15
Recom1.70 SMA20-22.94% SMA50-19.92% SMA20021.24% Volume1,883,601 Change0.31%
Sep-07-18Upgrade B. Riley FBR Neutral → Buy $18 → $19
Sep-06-18Reiterated Chardan Capital Markets Buy $17.50 → $24.50
Aug-08-18Reiterated Cantor Fitzgerald Overweight $13 → $18
Jul-02-18Reiterated Chardan Capital Markets Buy $9.50 → $16
May-09-18Upgrade Cantor Fitzgerald Neutral → Overweight $13
Mar-27-18Initiated Jefferies Buy $10
Feb-12-18Reiterated Cantor Fitzgerald Neutral $2 → $5
Feb-12-18Reiterated B. Riley FBR, Inc. Neutral $3 → $4
Jan-05-18Initiated B. Riley FBR, Inc. Neutral $3
Nov-27-17Upgrade Piper Jaffray Neutral → Overweight
Sep-18-17Upgrade William Blair Mkt Perform → Outperform
Nov-30-16Downgrade William Blair Outperform → Mkt Perform
Nov-30-16Downgrade Piper Jaffray Overweight → Neutral
Nov-30-16Downgrade Chardan Capital Markets Buy → Neutral $8 → $2
Nov-30-16Downgrade Cantor Fitzgerald Buy → Hold
Nov-10-16Reiterated Chardan Capital Markets Buy $10 → $8
Aug-18-16Initiated Cantor Fitzgerald Buy $15
May-19-16Initiated Chardan Capital Markets Buy $12
Sep-25-15Reiterated Piper Jaffray Overweight $12 → $20
Oct-09-14Downgrade RBC Capital Mkts Outperform → Sector Perform $35 → $9
Oct-15-18 07:30AM  Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 Business Wire
Oct-12-18 02:31PM  This 1 Stock Could Send the Entire Healthcare Sector Soaring -- or Plunging Motley Fool
Oct-11-18 03:58PM  Here's Why Arrowhead Pharmaceuticals Skyrocketed Almost 30% in September Motley Fool
12:05PM  Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018 Business Wire
Oct-10-18 10:30AM  Major Biotech Announcements Moving the Market ACCESSWIRE -8.14%
Oct-09-18 10:45AM  ARWR Stock Sinks After Signing a Big Collaboration Deal InvestorPlace
Oct-08-18 08:01AM  Is Arrowhead Pharmaceuticals, Inc. a Buy on the Dip? Motley Fool -6.72%
Oct-05-18 11:30AM  J&J Inks Deal With Arrowhead for Promising Liver Candidate Zacks
09:57AM  Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data Zacks
08:00AM  Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Amarin ACCESSWIRE
Oct-04-18 02:49PM  J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion Reuters -17.40%
12:17PM  [$$] Honey, I Shrunk the Biotech Deal The Wall Street Journal
11:30AM  Stocks - Apple, Amazon Fall in Pre-market; Barnes & Noble Surges Investing.com
10:12AM  Arrowhead Announces $3.7B License Agreement With Janssen For Gene-Silencing Drug Benzinga
09:19AM  J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion Reuters
07:52AM  UPDATE: Arrowhead Pharma stock surges 19% on news of $3.7 billion license agreement with Janssen MarketWatch
07:30AM  Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen Business Wire
Sep-25-18 07:30AM  Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences Business Wire
Sep-24-18 07:30AM  Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics Business Wire +5.23%
Sep-21-18 04:00PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire -5.88%
Sep-17-18 08:00AM  Today's Research Reports on Trending Tickers: Geron and Arrowhead Pharmaceuticals ACCESSWIRE
Sep-08-18 07:16AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Sep-07-18 02:10PM  Arrowhead Stock Is Not Done Rallying After Its 38% Jump InvestorPlace
08:00AM  Todays Research Reports on Stocks to Watch: Arrowhead Pharmaceuticals and Iovance Biotherapeutics ACCESSWIRE
07:55AM  The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering Benzinga
Sep-06-18 04:31PM  Why Cloudera, Arrowhead Pharmaceuticals, and MongoDB Jumped Today Motley Fool +37.52%
01:00PM  This Biotech Broke Out Bullishly On Its Experimental Hepatitis B Drug Investor's Business Daily
12:57PM  Here's What's Behind Arrowhead Pharmaceuticals' Soaring 41.8% Today Motley Fool
10:45AM  Healthcare Stocks Take Center Stage In September ACCESSWIRE
09:21AM  Arrowhead Pharmaceuticals stock rockets 30% after upbeat trial data prompts analyst upgrade MarketWatch
07:30AM  Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists Summit Business Wire
Aug-31-18 07:30AM  Arrowhead Completes Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Aug-30-18 04:00PM  Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences Business Wire
Aug-28-18 08:10AM  New Research Coverage Highlights MACOM Technology Solutions, Arrowhead Pharmaceuticals, PTC Therapeutics, Boot Barn, Darling Ingredients, and Endologix Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Aug-20-18 08:00AM  Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Perrigo Company ACCESSWIRE
Aug-19-18 11:40PM  Edited Transcript of ARWR earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-13-18 08:00AM  Today's Research Reports on Trending Tickers: Geron and Arrowhead Pharmaceuticals ACCESSWIRE
Aug-07-18 04:13PM  Arrowhead Research: Fiscal 3Q Earnings Snapshot Associated Press +6.04%
04:00PM  Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results Business Wire
02:30PM  Arrowhead Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 07:30AM  Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment from Amgen Business Wire
Jul-30-18 12:36PM  Why Arrowhead Pharmaceuticals, Inc. Stock Slumped Today Motley Fool -12.88%
Jul-24-18 07:30AM  Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Third Quarter Results Business Wire
Jul-19-18 10:26AM  Harry Boxers three drug stocks to watch MarketWatch
Jul-14-18 07:16AM  The 4 Best Biotech Stocks of 2018 (So Far) Motley Fool
Jul-13-18 08:00AM  Upcoming Catalysts Could Send This Unknown Stock Up 300% or More ACCESSWIRE
Jul-12-18 07:15AM  Free Pre-Market Technical Recap on ArQule and Three Additional Biotech ACCESSWIRE
Jul-11-18 09:15AM  3 Huge Biotech Winners in 2018 (So Far) Motley Fool
Jul-02-18 03:06PM  4 Biotech Stocks That Tripled in the First Half of 2018 Motley Fool +9.34%
Jun-29-18 07:30AM  Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference Business Wire +5.02%
Jun-28-18 06:33AM  The 3 Best Biotech Stocks of 2018 So Far Motley Fool
Jun-27-18 07:30AM  Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency Business Wire
Jun-26-18 08:30AM  Investor Expectations to Drive Momentum within AMC Entertainment, Arrowhead Pharmaceuticals, U.S. Silica, Catalent, RSP Permian, and KapStone Paper and Packaging Discovering Underlying Factors of Influence GlobeNewswire
Jun-21-18 08:07AM  3 Soaring Biotech Stocks. Can They Keep Climbing? Motley Fool
Jun-20-18 08:05AM  Arrowhead Pharmaceuticals Incs (NASDAQ:ARWR) Path To Profitability Simply Wall St. -6.35%
Jun-19-18 08:08AM  Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares Benzinga
08:00AM  Todays Research Reports on Stocks to Watch: Arrowhead Pharmaceuticals and ZIOPHARM Oncology ACCESSWIRE
Jun-18-18 03:11PM  Why Arrowhead Pharmaceuticals Stock Is Skyrocketing 23.3% Today Motley Fool +24.03%
07:30AM  Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Jun-13-18 07:05AM  Free Technical Reports on Arrowhead Pharma and Three Additional Biotech Equities ACCESSWIRE
Jun-08-18 04:30PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
May-31-18 08:22AM  Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time Benzinga
May-30-18 07:30AM  Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV Business Wire +5.73%
07:25AM  Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences Business Wire
May-21-18 08:00AM  Todays Research Reports on Stocks to Watch: Agile Therapeutics and Arrowhead Pharmaceuticals ACCESSWIRE
07:30AM  Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis Business Wire
May-15-18 11:52AM  Edited Transcript of ARWR earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
07:40AM  Wired News Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases ACCESSWIRE
May-14-18 07:30AM  Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV Business Wire
May-12-18 07:17AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
May-11-18 07:30AM  Arrowhead Pharmaceuticals Presents Preclinical Data on Expanding Cardiometabolic Pipeline Business Wire +8.33%
May-10-18 01:27PM  Four momentum stocks to watch amid earnings reports MarketWatch
09:44AM  Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results Benzinga
May-09-18 08:00AM  Recent Analysis Shows Extreme Networks, Lumber Liquidators, Owens-Illinois, Arrowhead Pharmaceuticals, Intrepid Potash, and General Cable Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire +16.13%
May-08-18 04:16PM  Arrowhead Research: Fiscal 2Q Earnings Snapshot Associated Press
04:00PM  Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results Business Wire
May-01-18 07:30AM  Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics Business Wire
Apr-24-18 04:01PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Second Quarter Results Business Wire
Apr-11-18 07:00AM  Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress Business Wire +6.95%
Mar-28-18 07:30AM  Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress Business Wire
Mar-27-18 07:30AM  Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B Business Wire
Mar-20-18 04:05PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
Mar-12-18 07:30AM  Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Mar-07-18 08:30AM  Detailed Research: Economic Perspectives on Etsy, Tiffany, First BanCorp, Deere, Callaway Golf, and Arrowhead Pharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-06-18 07:30AM  Arrowhead to Present at Barclays Global Healthcare Conference 2018 Business Wire
Feb-27-18 08:30AM  Todays Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Zosano Pharma ACCESSWIRE
Feb-22-18 07:30AM  Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Feb-15-18 01:32PM  Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT Business Wire +6.58%
07:30AM  Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B Business Wire
Feb-12-18 06:38PM  Edited Transcript of ARWR earnings conference call or presentation 9-Feb-18 9:30pm GMT Thomson Reuters StreetEvents -5.01%
Feb-09-18 04:09PM  Arrowhead Research reports 1Q loss Associated Press
04:00PM  Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results Business Wire
12:00PM  Arrowhead Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-07-18 08:28AM  [$$] OppenheimerFunds' Big Biotech Stock Buys Barrons.com
Feb-02-18 04:00PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2018 First Quarter Results Business Wire
Jan-25-18 09:02AM  Taking Stock of Arrowhead Pharmaceuticals Financial Performance Market Realist
07:32AM  What Led to Arrowhead Pharmaceuticals Revenue Surge in 2017? Market Realist
Jan-24-18 01:30PM  Arrowheads Candidates for Hepatitis B, Cardiovascular Diseases Market Realist
12:00PM  Taking a Closer Look at Arrowhead Pharmaceuticals TRIM Platform Market Realist
10:25AM  Analysts Recommendations for Arrowhead and Its Peers Market Realist
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and with Janssen Pharmaceuticals, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Myszkowski Kenneth AllenChief Financial OfficerSep 06Option Exercise3.5745,000160,500355,815Sep 10 06:32 PM
Myszkowski Kenneth AllenChief Financial OfficerSep 06Sale19.3445,000870,200310,815Sep 10 06:32 PM
Anzalone Christopher RichardChief Executive OfficerSep 04Sale14.4564,834936,8511,803,955Sep 05 04:23 PM
Anzalone Christopher RichardChief Executive OfficerAug 31Sale14.45100,0001,445,0001,868,789Sep 05 04:23 PM
Myszkowski Kenneth AllenChief Financial OfficerJun 19Option Exercise2.0120,00040,200330,815Jun 20 09:18 PM
Myszkowski Kenneth AllenChief Financial OfficerJun 19Sale14.0120,000280,200310,815Jun 20 09:18 PM
Myszkowski Kenneth AllenChief Financial OfficerMay 31Option Exercise2.0112,60025,326323,415Jun 01 05:34 PM
Myszkowski Kenneth AllenChief Financial OfficerMay 31Sale11.0012,600138,600310,815Jun 01 05:34 PM
Myszkowski Kenneth AllenChief Financial OfficerMay 30Option Exercise2.011,4002,814312,215Jun 01 05:34 PM
Myszkowski Kenneth AllenChief Financial OfficerMay 30Sale11.001,40015,400310,815Jun 01 05:34 PM
GIVEN DOUGLAS BDirectorApr 24Sale6.6325,000165,750155,000Apr 25 07:40 PM
Myszkowski Kenneth AllenChief Financial OfficerMar 27Option Exercise2.0120,00040,200330,815Mar 27 07:46 PM
Myszkowski Kenneth AllenChief Financial OfficerMar 27Sale8.0020,000160,000310,815Mar 27 07:46 PM
Anzalone Christopher RichardChief Executive OfficerMar 16Sale7.4026,000192,4001,968,789Mar 16 06:09 PM
Anzalone Christopher RichardChief Executive OfficerMar 15Sale7.41100,000741,0001,994,789Mar 15 06:58 PM
Anzalone Christopher RichardChief Executive OfficerMar 14Sale7.44100,000744,0002,094,789Mar 15 06:58 PM
Anzalone Christopher RichardChief Executive OfficerMar 13Sale7.43100,000743,0002,194,789Mar 15 06:58 PM
GIVEN BRUCE DChief Operating OfficerMar 05Sale6.7320,000134,600908,356Mar 05 08:48 PM
GIVEN BRUCE DChief Operating OfficerJan 01Sale3.6920,00073,800928,356Jan 03 07:25 PM